Concepedia

Dose Escalation Endpoints

Dose Escalation Endpoints is a methodological construct in clinical pharmacology that specifies the predefined criteria or outcomes used to determine the safety, tolerability, and optimal biological activity of increasing drug dosages in phase I trials.

53

Publications

2.9K

Citations

579

Authors

266

Institutions

Publications per year

2017–2026

20

Parents

Publications

53

Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

Raffit Hassan, Susie Bullock, Ahalya Premkumar et al. · Clinical Cancer Research · 2007 · 381 citations · Full text

, , +16

Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer

Sunil R. Hingorani, William Proctor Harris, J. Thaddeus Beck et al. · Clinical Cancer Research · 2016 · 323 citations · Full text

, , +13

Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis

David J. Hunter, Marilyn C. Pike, Beth Jonas et al. · BMC Musculoskeletal Disorders · 2010 · 152 citations · Full text

, , +16

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors

Antoinette R. Tan, Eric H. Rubin, Diana C. Walton et al. · Clinical Cancer Research · 2009 · 137 citations

, , +14

An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure

Marc S. Penn, Farrell O. Mendelsohn, Gary L. Schaer et al. · Circulation Research · 2013 · 133 citations

, , +14

1–5 of 53

Authors

579

  1. JB
    Jair Bar

    Sheba Medical Center, Israel

    2 publications · 65 citations

    2

    h-index

  2. CJ
    Charles J. Hodge

    SUNY Upstate Medical University, United States

    2 publications · 58 citations

    2

    h-index

  3. MK
    Muaiad Kittaneh

    The Barbara Ann Karmanos Cancer Institute, United States

    2 publications · 84 citations

    2

    h-index

  4. GI
    Geoffrey I. Shapiro

    Dana-Farber Cancer Institute, United States

    2 publications · 48 citations

    2

    h-index

  5. SS
    Seung S. Hahn

    SUNY Upstate Medical University, United States

    2 publications · 58 citations

    2

    h-index

1–5 of 579

Institutions

266

  1. The University of Texas MD Anderson Cancer Center

    Houston, United States

    5 h-index

    10 publications

    375 citations

  2. Dana-Farber Cancer Institute

    Boston, United States

    5 h-index

    9 publications

    273 citations

  3. Sarah Cannon

    Nashville, United States

    5 h-index

    11 publications

    576 citations

  4. Memorial Sloan Kettering Cancer Center

    New York, United States

    4 h-index

    4 publications

    123 citations

  5. Tennessee Oncology

    Nashville, United States

    4 h-index

    7 publications

    395 citations

  6. Vanderbilt University

    Nashville, United States

    4 h-index

    13 publications

    420 citations

  7. Columbia University Irving Medical Center

    New York, United States

    4 h-index

    14 publications

    1.5K citations

  8. The Barbara Ann Karmanos Cancer Institute

    Detroit, United States

    3 h-index

    4 publications

    156 citations

1–8 of 266

Venues

  1. Journal of Clinical Oncology

    12 publications · 265 citations

    11

    h-index

  2. Clinical Cancer Research

    7 publications · 1.1K citations

    7

    h-index

  3. British Journal of Cancer

    BJC · 3 publications · 229 citations

    3

    h-index

  4. Blood Advances

    2 publications · 94 citations

    2

    h-index

  5. Investigational New Drugs

    2 publications · 69 citations

    2

    h-index

1–5